MichaelJosephLouieMD

PubMed

• 1 citations
  Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials.
  Francisco J. Tinahones, U. Laufs, Bertrand Cariou, Michael J. Louie, J. Yang, Desmond Thompson, Lawrence A. Leiter> ;Diabetes & Metabolism. 2020 Sep 1
• 6 citations
  Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry.
  Angela Lowenstern, Shuang Li, Salim S. Virani, Ann Marie Navar, Zhuokai Li, Jennifer G. Robinson, Véronique L. Roger, Anne C. Goldberg, Andrew Koren, Michael J. Louie,...> ;American Heart Journal. 2020 Jul 1
• 2 citations
  The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device.
  Juan Pablo Frias, Michael J. Koren, Virginie Loizeau, Ana Merino-Trigo, Michael J. Louie, Mary Alice Raudenbush, Isabela Batsu> ;Clinical Therapeutics. 2020 Jan 1
• 31 citations
  Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment ...
  Matthew T. Roe, Qian H Li, Deepak L. Bhatt, Vera Bittner, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Patricio Lopez-Jaramillo, Renato D. Lo...> ;Circulation. 2019 Nov 5
• 8 citations
  Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry
  Ying Xian, Ann Marie Navar, Shuang Li, Zhuokai Li, Jennifer G. Robinson, Salim S. Virani, Michael J. Louie, Andrew Koren, Anne C. Goldberg, Véronique L. Roger, Peter W...> ;Journal of the American Heart Association. 2019 Oct 1
• 32 citations
  Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome ― The ODYSSEY J-IVUS Trial ―
  Junya Ako, Kiyoshi Hibi, Kenichi Tsujita, Takafumi Hiro, Yoshihiro Morino, Ken Kozuma, Toshiro Shinke, Hiromasa Otake, Kiyoko Uno, Michael J. Louie, Yoshiharu Takagi, ...> ;Circulation Journal. 2019 Sep 25
• 47 citations
  Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
  Kausik K. Ray, Antonio J. Vallejo-Vaz, Henry N. Ginsberg, Michael H. Davidson, Michael J. Louie, Maja Bujas-Bobanovic, Pascal Minini, Robert H. Eckel, Christopher P. C...> ;Atherosclerosis. 2019 Sep 1
• 1 citations
  Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies
  Frederick J. Raal, Jaakko Tuomilehto, Andrei C. Sposito, Francisco Antonio Helfenstein Fonseca, Maurizio Averna, Michel Farnier, Raul D. Santos, Keith C. Ferdinand, R....> ;Journal of Clinical Lipidology. 2019 Sep 1
• 16 citations
  Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid ...
  Michael G. Nanna, Ann Marie Navar, Tracy Y. Wang, Shuang Li, Salim S. Virani, Zhuokai Li, Jennifer G. Robinson, Véronique L. Roger, Peter W.F. Wilson, Anne C. Goldberg...> ;American Heart Journal. 2019 May 22
• 126 citations
  Sex Differences in the Use of Statins in Community Practice.
  Michael G. Nanna, Tracy Y. Wang, Qun Xiang, Anne C. Goldberg, Jennifer G. Robinson, Véronique L. Roger, Salim S. Virani, Peter W.F. Wilson, Michael J. Louie, Andrew Ko...> ;Circulation. Cardiovascular Quality and Outcomes. 2019 Aug 1
• 2 citations
  PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab
  Eric Bruckert, Dean J. Kereiakes, Michael J. Koren, Michael J. Louie, Alexia Letierce, Kathryn Miller, Christopher P. Cannon> ;Journal of Clinical Lipidology. 2019 May 1
• 130 citations
  Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry.
  Corey K. Bradley, Tracy Y. Wang, Shuang Li, Jennifer G. Robinson, Véronique L. Roger, Anne C. Goldberg, Salim S. Virani, Michael J. Louie, L. Veronica Lee, Eric D. Pet...> ;Journal of the American Heart Association. 2019 Apr 2
• 15 citations
  Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A Survey of US Practice in the PALM Registry)
  Angela Lowenstern, Ann Marie Navar, Shuang Li, Salim S. Virani, Anne C. Goldberg, Michael J. Louie, L. Veronica Lee, Eric D. Peterson, Tracy Y. Wang> ;The American Journal of Cardiology. 2019 Apr 1
• 9 citations
  Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry.
  Angela Lowenstern, Shuang Li, Ann Marie Navar, Véronique L. Roger, Jennifer G. Robinson, Anne C. Goldberg, Salim S. Virani, L. Veronica Lee, Peter W.F. Wilson, Michael...> ;Journal of the American Heart Association. 2018 Sep 18
• 23 citations
  Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
  Marja-Riitta Taskinen, Stefano Del Prato, Maja Bujas-Bobanovic, Michael J. Louie, Alexia Letierce, Desmond Thompson, Helen M. Colhoun> ;Atherosclerosis. 2018 Jul 21
• 9 citations
  Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
  Robert R. Henry, Dirk Müller-Wieland, Pam R. Taub, Maja Bujas-Bobanovic, Michael J. Louie, Alexia Letierce, Henry N. Ginsberg> ;Diabetes, Obesity & Metabolism. 2018 Jul 1
• 63 citations
  Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease
  Peter P. Toth, Jamie P. Dwyer, Christopher P. Cannon, Helen M. Colhoun, Daniel J. Rader, Ashish Upadhyay, Michael J. Louie, Andrew Koren, Alexia Letierce, Jonas Mandel...> ;Kidney International. 2018 Jun 1
• 14 citations
  Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
  Henry N. Ginsberg, Michel Farnier, Jennifer G. Robinson, Christopher P. Cannon, Naveed Sattar, Marie T. Baccara-Dinet, Alexia Letierce, Maja Bujas-Bobanovic, Michael J...> ;Diabetes Therapy. 2018 May 19
• 51 citations
  Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry
  Michael G. Nanna, Ann Marie Navar, Tracy Y. Wang, Xiaojuan Mi, Salim S. Virani, Michael J. Louie, L. Veronica Lee, Anne C. Goldberg, Véronique L. Roger, Jennifer G. Ro...> ;Journal of the American Heart Association. 2018 May 8
• Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocuma...
  Harold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, Michael J Louie, Desmond Thompson, G Kees Hovingh> ;Cardiovascular Drugs and Therapy. 2018 Apr 1
• 7 citations
  Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
  Harold E Bays, Robert S Rosenson, Marie T Baccara-Dinet, Michael J Louie, Desmond Thompson, G Kees Hovingh> ;Cardiovascular Drugs and Therapy. 2018 Apr 1
• 15 citations
  Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) ...
  Angela Lowenstern, Shuang Li, Ann Marie Navar, Salim S. Virani, L. Veronica Lee, Michael J. Louie, Eric D. Peterson, Tracy Y. Wang> ;American Heart Journal. 2018 Mar 24
• 38 citations
  Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.
  Lawrence A. Leiter, José Luis Zamorano, Maja Bujas-Bobanovic, Michael J. Louie, Guillaume Lecorps, Christopher P. Cannon, Yehuda Handelsman> ;Diabetes, Obesity &amp; Metabolism. 2017 Jul 1
• 12 citations
  Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials
  Alberico L. Catapano, L. Veronica Lee, Michael J. Louie, Desmond Thompson, Jean Bergeron, Michel Krempf> ;Scientific Reports. 2017 Apr 4
• 104 citations
  Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
  Daniel Gaudet, Gerald F. Watts, Jennifer G. Robinson, Pascal Minini, William J. Sasiela, Jay M. Edelberg, Michael J. Louie, Frederick J. Raal> ;The American Journal of Cardiology. 2017 Jan 1
• Join now to see all